Genentech, Inc.

Seattle Genetics, Inc.

Genencor International, Inc.

Immunex Corporation

Genetech, Inc.

Carter and Son Toolworks LLC

Seagen Inc.

F. Hoffmann-la Roche Ag

Paul J Carter

Leonard G Presta

Charlotte McDonagh

John B Ridgway

Dennis R Benjamin

Christoph Spiess

Charles G Cerveny

W Robert Arathoon

Anne M Merchant

James A Wells

Henry Bernard Lowman

Django Sussman

Isidro Hotzel

Teemu T Junttila

Yiyuan Yin

Ji Li

Diego Ellerman

Danielle Dicara

David Carter

Resi B Gerstner

Austin L Gurney

Michael Patrick Dillon

Justin M Scheer

Camellia W Adams

Che-Leung Law

Brian M Fendly

Julie A McEarchern

Jianhui Zhou

Hongxing Zhou

Jacob Corn

Qianting Zhai

Mike Mahoney

Charlotte Mcdonagh

Avi J Ashkenazi

Kyung Jin Kim

William Matthews

Nancy Chiang

Junichiro Sonoda

Justin Scheer

Mark Chen

Wendy N Sandoval

Hans Peter Gerber

Leigh Francisco

Maria L Rodrigues

Wendy Sandoval

Julie Mcearchern

The invention provides anti-hypusine antibodies and their use in detecting and isolating polypeptides containing hypusine and/or deoxyhypusine, as well as compositions and kits comprising the anti-hypusine antibodies.

Anti-hypusine antibodies and uses thereof

Provided are, inter alia, multispecific antigen binding proteins, or antigen-binding fragments thereof, comprising one or more mutations in the VH/VL domains and/or CH1/CL domains, pharmaceutical compositions comprising same, isolated nucleic acids, vectors, and host cells encoding/expressing same, method of making the multispecific antigen binding proteins, computer readable media for evaluating multispecific antigen binding proteins, and libraries.

Multispecific antigen-binding proteins

The present invention relates to anti-FcRH5 antibodies, including anti-FcRH5 antibodies comprising an FcRH5 binding domain and a CD3 binding domain (e.g., FcRH5 T cell-dependent bispecific (TDB) antibodies), and methods of using the same.

Humanized and affinity matured antibodies to FcRH5 and methods of use

This invention, among other things, relates to CD19 binding agents and methods of using such CD binding agents for treating disease.

CD19 binding agents and uses thereof

A handheld wood thread cutting tool with an elongated shank formed with a planar surface and including a first end and a second end with a length substantially longer than its width. The first end has a first wood thread cutting edge aligned substantially in parallel relative to a first vertical plane perpendicular to the planar surface and passing through the length of the elongated shank from the first end to the second end. The second end has a second wood thread cutting edge aligned substantially parallel to a second vertical plane perpendicular to the planar surface and running through the width of the elongated shank from a first side wall to a second side wall. A ball handle is affixed between the first and the second end.

Handheld wood thread cutting tool

Wood threading tool

The present invention provides variant target binding agents and methods relating to the use of such binding agents for the prophylaxis or treatment of cancers and immunological disorders. The variant target binding agent is conjugated to a therapeutic agent that exerts a cytotoxic, cytostatic, or immunomodulatory effect on target cells.

Variant target binding agents and uses thereof

The invention provides dual specific anti-FGFR2 and FGFR3 (FGFR2/3) antibodies, and compositions comprising and methods of using these antibodies.

Anti-FGFR2/3 antibodies and methods using same

This invention relates to CD19 binding agents and methods of using such CD19 binding agents for treating disease.

Disclosed are CD70 binding agents, such as humanized anti-CD70 antibodies and fragments and derivatives, that exert a cytotoxic, cytostatic or immunomodulatory on CD70 expressing cells, as well as pharmaceutical compositions and kits comprising the antibody, fragment or derivative. Also disclosed are methods for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the CD70 binding agents or pharmaceutical compositions.

Humanized anti-CD70 binding agents and uses thereof

Growing community of inventors

San Francisco, CA, United States of America

Paul J Carter